Your session is about to expire
← Back to Search
Enzyme
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure (DAMPENCOVID Trial)
Phase 2
Recruiting
Research Sponsored by Jon Simmons
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
All Individual Drugs Already Approved
Summary
This trial will test if inhaling a medication called Dornase Alpha can help COVID-19 patients with severe lung problems breathe better and reduce their risk of dying.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mortality at 28 days
Systemic Therapeutic Response
Secondary study objectives
Legnth of Hospital Stay
Legnth of ICU Stay
Pulmonary Function
+1 moreAwards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment ArmExperimental Treatment1 Intervention
Patient will receive 2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
Group II: Placebo Arm 0.9% sodium chloridePlacebo Group1 Intervention
Patient will receive 2.5ml of Sodium Chloride 0.9% aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses.
Find a Location
Who is running the clinical trial?
Jon SimmonsLead Sponsor
University of South AlabamaOTHER
43 Previous Clinical Trials
15,724 Total Patients Enrolled